Intravenous Thrombolysis

Stroke: Pathophysiology, Diagnosis, and Management

Volumn , Issue , 2004, Pages 919-941

  Al Khoury, Lama ^a   Lyden, Patrick D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942585491     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-44-306600-0/50056-0     Document Type: Chapter

References (78)

1. Tissue plasminogen activator for acute ischemic stroke NINDS rt-PA Stroke Study Group. N Engl J Med 1995, 333:1581-1587.
2. Lyden PD Thrombolytic Therapy for Stroke 2001, Humana Press, Totowa, NJ.
3. Douglas S Coagulation history. Br J Haematol 1999, 107:22-32.
4. Collen D Fibrin-selective thrombolytic therapy for acute myocardial infarction. Circulation 1996, 93:857-865.
5. Cannon CP Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol 1994, 24:1602-1610.
6. Cairns J, Fuster V, Gore J, Kennedy JW Coronary thrombolysis. Cardiopulmon Crit Care J 1995, 108:401S-423S.
7. Verstraete M Third generation thrombolytic drugs. Am J Med 2000, 109:52-58.
8. Benedict CR, Refino CJ, et al. New variant of human tissue plasminogen activator (tPA) with enhanced efficacy and a lower incidence of bleeding compared with recombinant human tPA. Circulation 1995, 92:3032-3040.
9. Van de Werf F, Cannon C, Luyten A, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial. Am Heart J 2000, 137:786-791.
10. Van de Werf F, Barron HV, Armstrong P, et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents. Eur Heart J 2001, 22:2253-2261.
11. The TNK for Stroke Investigators Pilot study in tenecteplase (TNK) in acute ischemic stroke: Preliminary report [Abstract]. Stroke 2003, 34:246.
12. Meyer JS, Gilroy J, Barnhart ME, et al. Therapeutic thrombolysis in cerebral thromboembolism. Cerebral Vascular Diseases 1963, 160-175. Grune & Stratton, Philadelphia. W. Siekert, J.G.S. Whisnant (Eds.).
13. del Zoppo G, Copeland BR, Waltz TA, et al. The beneficial effect of intracarotid urokinase on acute stroke in a baboon model. Stroke 1986, 17:638-643.
14. Zivin JA, Fisher M, DeGirolami U, et al. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985, 230:1289-1292.
15. del Zoppo G, Copeland BR, Harker LA, et al. Experimental acute thrombotic stroke in baboons. Stroke 1986, 17:1254-1265.
16. Slivka A, Pulsinelli WA Hemorrhagic complications of thrombolytic therapy in experimental stroke. Stroke 1987, 18:1148-1156.
17. Lyden PD, Zivin JA, Clark WA, et al. Tissue plasminogen activator mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits. Neurology 1989, 39:703-708.
18. Clark WM, Madden KP, Lyden PD, Zivin JA Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits. Stroke 1991, 22:872-876.
19. Lyden PD, Madden KP, Clark WA, et al. Comparison of cerebral hemorrhage rates following tissue plasminogen activator or streptokinase treatment for embolic stroke in rabbits. Stroke 1990, 21:981-983.
20. Meyer JS, Gilroy J, Barnhart ME, Johnson JF Therapeutic thrombolysis in cerebral thromboembolism: Randomized evaluation of intravenous streptokinase. Cerebral Vascular Diseases, Fourth Princeton Conference 1965, 200-213. Grune & Stratton, New York. C.H. Millikan, R.G. Siekert, J.P. Whisnant (Eds.).
21. Fletcher AP, Alkjaersig N, Lewis M, et al. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976, 7:135-142.
22. del Zoppo G, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992, 32:78-86.
23. Brott TG, Haley EC, Levy DE, et al. Urgent therapy for stroke. Part I: Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992, 23:632-640.
24. Haley EC, Levy DE, Brott TG, et al. Urgent therapy for stroke. Part II: Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992, 23:641-645.
25. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992, 42:976-982.
26. Haley EC, Brott TG, Sheppard GL, et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke 1993, 24:1000-1004.
27. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995, 274:1017-1025.
28. Hacke W, Bluhmki E, Steiner T, et al. Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set. Stroke 1998, 29:2073-2075.
29. Steiner T, Bluhmki E, Kaste M, et al. The ECASS 3-hour cohort. Cerebrovasc Dis 1998, 8:198-203.
30. Haley EC, Lewandowski C, Tilley BC, et al. Myths regarding the NINDS rt-PA stroke trial: Setting the record straight. NINDS rt-PA Stroke Study Group. Ann Emerg Med 1997, 30:676-682.
31. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke NINDS rt-PA Stroke Study Group. Stroke 1997, 28:2109-2118.
32. Kwiatkowski TG, Libman R, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 1999, 340:1781-1787.
33. Broderick JP, Lu M, Kothari R, et al. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke 2000, 31:2335-2341.
34. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998, 352:1245-1251.
35. Multicenter Acute Stroke Trial-Europe Study Group (MAST-E): Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996, 335:145-150.
36. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Lancet 1995, 346:1509-1514.
37. Donnan GA, Davis SM, Chambers BR, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996, 276:961-966.
38. Donnan GA, Davis SM, Chambers BR, et al. ASK Trial: Unfavourable outcome if treated more than three hours after onset [abstract]. Cerebrovasc Dis 1995, 5:225-273.
39. Cornu C, Boutitie F, Candelise L, et al. Streptokinase in acute ischemic stroke: An individual patient data meta-analysis: The Thrombolysis in Acute Stroke Pooling Project. Stroke 2000, 31:1555-1560.
40. Clark WM, Albers GW, For the Atlantis Stroke Study Investigators The ATLANTIS rt-PA (alteplase) acute stroke trial: Final results. 24th American Heart Association International Conference on Stroke and Cerebral Circulation; oral presentation [Abstract]. Stroke 1999, 30:234.
41. Clark W, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. JAMA 1999, 282:2019-2024.
42. Albers GW, Clark W, Madden K, Hamilton S ATLANTIS Trial: Results for patients treated within 3 hours of stroke onset. Stroke 2002, 33:493-496.
43. Chiu D, Krieger D, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute ischemic stroke feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998, 29:18-22.
44. Grond M, Stenzel C, Schmulling S, et al. Early intravenous thrombolysis for acute ischemic stroke in a community based approach. Stroke 1998, 29:1544-1549.
45. Egan R, Lutsep HL, Clark WM, et al. Open label tissue plasminogen activator for stroke: The Oregon experience. J Stroke Cerebrovasc Dis 1999, 8:287-290.
46. Katzan I, Furlan A, Lloyd L, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience. JAMA 2000, 283:1151-1158.
47. Katzen IMM, Hammer MDM, Furlan AJM Quality improvement and tissue-type plasminogen activator for acute stroke. A Cleveland update. Stroke 2003, 34:799-800.
48. Albers GW, Bates V, Clark W, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000, 283:1145-1150.
49. Chapman KM, Woolfenden AR, Graeb D, et al. Intravenous tissue plasminogen activator for acute ischemic stroke. Stroke 2000, 31:2920-2924.
50. Barber PA, Zhang J, Demchuk A, et al. Why are stroke patients excluded from TPA therapy?. Neurology 2001, 56:1015-1020.
51. Koennecke HC, Nohr R, Leistner S, Marx P Intravenous tPA for ischemic stroke team: Performance over time, safety and efficacy in a single center-2-year experience. Stroke 2001, 32:1074-1078.
52. Grotta J, Burgin WS, El-Mitwalli A, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke. Arch Neurol 2001, 58:2009-2013.
53. Hill MD, Buchan AM Canadian Activase for Stroke Effectiveness Study (CASES). Can J Neurol Sci 2001, 28:232-238.
54. Trouillas P, Nighoghossian N, Derex L, et al. Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke. Determination of etiological, topographic, and radiological outcome factors. Stroke 1998, 29:2529-2540.
55. Trouillas P, Nighoghossian N, Derex L, Honnorat J Prognosis at 5 years of acute cerebral infarcts of the carotid territory treated by intravenous rtPA: Data from the Lyon thrombolysis registry. Stroke 2002, 33:395.
56. Trouillas P, Nighoghossian N, Derex L, Final results of the Lyon rtPA within 7 hours without radiological and clinical exclusions in carotid territory acute cerebral infarcts [Letter].
57. Adams HP, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. Circulation 1996, 94:1167-1174.
58. Grotta J, Alexandrov AV Early arterial re-occlusion in patients treated with 0.9 mg/kg IV TPA [abstract]. Stroke 2002, 33:354.
59. Lyden P, Lu M, Kwiatkowski TG, et al. Thrombolysis in patients with transient neurologic deficits. Neurology 2001, 57:2125-2128.
60. Hemmen TM, Meyer BC, Hayes KA, et al. Identification of "stroke mimics" among 411 code strokes at the UCSD Stroke Center from September 1998 to March 2001 [Abstract]. Stroke 2002, 33:385.
61. Wein TH, Hickenbottom SL, Morgenstern B, et al. Safety of tissue plasminogen activator for acute stroke in menstruating women. Stroke 2002, 33:2506-2508.
62. von Kummer R, Allen KL, Holle R, et al. Acute stroke: Usefulness of early CT findings before thrombolytic therapy. Radiology 1997, 205:327-333.
63. Patel S, Levine S, Tilley B, et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001, 286:2830-2838.
64. Gilligan A, Markus R, Read S, et al. Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke. Stroke 2002, 33:2236-2242.
65. Barber P, Demchuk A, Hudon ME, et al. Hyperdense sylvian fissure MCA "dot" sign. Stroke 2001, 32:84-88.
66. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: The NINDS rt-PA stroke study. Neurology 2000, 55:1649-1655.
67. Generalized efficacy of t-PA for acute stroke NINDS rt-PA Stroke Study Group. Stroke 1997, 28:2119-2125.
68. Alexandrov AV, Grotta JC Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002, 59:862-867.
69. Brott TG, Reed RL, Antihypertensive therapy in stroke: Medical therapy of acute stroke. 117-141, 1989.
70. Brott T, Lu M, Kothari R, et al. Hypertension and its treatment in the NINDS rt-PA stroke trial. Stroke 1998, 29:1504-1509.
71. Demchuck AM, Tanne D, Hill MD, et al. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology 2001, 57:474-480.
72. The NINDS t-PA Stroke Study Group Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997, 28:2109-2118.
73. Fagen SC, Morgenstern LB, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 1998, 50:883-890.
74. von Kummer R, Hacke W Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 1992, 23:646-652.
75. Zivin J, Mazzarella V Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke. Arch Neurol 1991, 48:1235-1238.
76. Zhang RL, Zhang ZG, Chopp M Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat. Neurology 1999, 52:273-279.
77. Grotta J Combination therapy stroke trial. Cerebrovasc Dis 2001, 12:258-263.
78. Lyden P, Jacoby M, Schim J, et al. The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): Final results. Neurology 2001, 57:1199-1205.